Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Blood (2020) 136 (Supplement 1): 36–38.

https://doi.org/10.1182/blood-2020-137334

Published: 2020

Journal Articles

Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study

Giuseppe Gritti, MD PhD, Paula Marlton, MBBS FRACP FRCPA, Tycel J. Phillips, MD, Christopher Arthur, Rajat Bannerji, MDPhD, Paolo Corradini, Anna Johnston, John F. Seymour, Sam Yuen, MBBS, FRACP, FRCPA, Jamie Hirata, Lisa Musick, Sourish Saha, Brandon Croft, Christopher Flowers, MDMS

Blood (2020) 136 (Supplement 1): 45–47.

https://doi.org/10.1182/blood-2020-136361

Published: 2020

Journal Articles

The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3 -ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3 -ITD Acute Myeloid Leukemia (ALLG AMLM16)

Natasha S Anstee, PhD, Giovanna Pomilio, Mark Levis, MD PhD, Sarah MacRaild, Michael Murray, PhD DSc, Tristan Rawling, PhD, Glen A Kennedy, MBBS FRACP FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Anthony Schwarer, MBBS, MD FRACP, FRCPA, Anoop Kumar Enjeti, MBBS,FRCPA, FRACP, PhD MD MRCP, James D'Rozario, MBBS, FRACP, FRCPA, Paula Marlton, MBBS FRACP FRCPA, Ian Bilmon, BMBS, FRACP, FRCPA, Adam Ivey, BSc, MSc, PhD, Doen Ming Ong, MBBS, Andrew W Roberts, MBBS, Andrew H Wei, MBBS, PhD

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-141711

Published: 2020

Journal Articles

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Gavin Cull, MB, BS, FRACP, FRCPA, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, Jan A. Burger, MD PhD, Judith Trotman, MBChB, FRACP, FRCPA, Paula Marlton, MBBS (Hons), FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Javier Munoz, MD MS, FACP, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Ken Wu, PhD, Siminder Atwal, PhD, William Novotny, MD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 500.

https://doi.org/10.1182/blood-2019-125483

Published: 2019

Journal Articles

High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan

Daniel J. DeAngelo, MD PhD, Brian A Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, MD, Anjali S. Advani, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Michael E O'Dwyer, MD, William E. Fogler, PhD, John L. Magnani, PhD, Mary M Chen, MD PhD, Eric J. Feldman, MD, Helen M Thackray, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2690.

https://doi.org/10.1182/blood-2019-123744

Published: 2019

Journal Articles

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Daniel J. DeAngelo, MD PhD, Harry P. Erba, MD PhD, Brian A Jonas, MD PhD, Michael E O'Dwyer, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Gerwin Huls, MD PhD, Jane L. Liesveld, MD, Brenda Cooper, MD, Bhavana Bhatnagar, DO, Geoffrey L. Uy, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Michael B. Armstrong, MD PhD, William E. Fogler, PhD, Mary M Chen, MD PhD, John L. Magnani, PhD, Helen M Thackray, MD, Eric J. Feldman, MD, Anjali S. Advani, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2650.

https://doi.org/10.1182/blood-2019-123816

Published: 2019

Journal Articles

GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study

Daniel J. DeAngelo, MD, Brian A Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, Anjali S. Advani, MD, Paula Marlton, MBBS, Michael O'Dwyer, MD, John L Magnani, PhD, Helen M. Thackray, MD, Pamela S. Becker, MD PhD

Blood (2017) 130 (Supplement 1): 894.

https://doi.org/10.1182/blood.V130.Suppl_1.894.894

Published: 2017

Journal Articles

Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non Hodgkin's Lymphoma

Constantine S. Tam, MBBS, MD FRACP, FRCPA, David Simpson, MBChB, Stephen Opat, FRACP, FRCPA, Won Seog Kim, MD, Ph. D., Michael Wang, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Patrick B Johnston, MD PhD, Javier Munoz, MD, Won-Sik Lee, MD, Paula Marlton, MBBS, David Gottlieb, MBBS, MD FRACP, FRCPA, Lai Wang, PhD, Jane Huang, MD, James Hilger, Ling Xue, PhD, Sunhee Ro, PhD, Judith Trotman, FRACP

Blood (2017) 130 (Supplement 1): 152.

https://doi.org/10.1182/blood.V130.Suppl_1.152.152

Published: 2017

Journal Articles

Metabolic Profiling of Adult Acute Myeloid Leukemia (AML)

Blood (2016) 128 (22): 1684.

https://doi.org/10.1182/blood.V128.22.1684.1684

Published: 2016

Journal Articles

High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study

Constantine S. Tam, MBBS, Judith Trotman, MBChB, Stephen Opat, MD, Paula Marlton, MBBS, Gavin Cull, MBBS DM FRACP FRCPA, David Simpson, MBChB, FRACP, FRCPA, Matthew Ku, MBBS, David Ritchie, MD PhD, Emma Verner, FRACP, FRCPA, MBBS, Sumita Ratnasingam, MBBS, Mary Ann Anderson, MBBS, Peter Wood, MD FRACP, FRCPA, MBBS, Mark Kirschbaum, MD, Lai Wang, PhD, Ling Xue, Jianxin Yang, Eric Hedrick, John F Seymour, Andrew W. Roberts

Blood (2016) 128 (22): 1216.

https://doi.org/10.1182/blood.V128.22.1216.1216

Published: 2016

Journal Articles

Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival

Bradstock Kenneth, Emma Link, DPhil, Juliana Di Iulio, BAppSc, PhD, Jeff Szer, MB, BS, FRACP, Paula Marlton, MBBS, FRCPA, FRACP, Andrew Wei, MBBS, PhD, Arno Enno, MB,BS,FRCPA, FRACP, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Ian D. Lewis, MBBS PhDFRACP FRCPA, James D'Rozario, MB BS FRACP, Luke Coyle, MBBS, FRACP, FRCPA, Gavin Cull, MBBS DM FRACP FRCPA, Philip Campbell, MB ChB FRACP FRCPA, Michael Francis Leahy, FRACP, Uwe H Hahn, MDFGCP FRCPA, Paul Cannell, MD, Campbell Tiley, MBBS,FRACP, FRCPA, Raymond M. Lowenthal, MD FRACP, FRCP, John Moore, MBBS, MD FRACP , FRCPA, Kimberly Cartwright, FRACP,MDFRCPA, Ilona Cunningham, John Taper, MBBS FRACP FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Andrew W. Roberts, MBBS PhD, Warwick John Benson, Mark S Hertzberg, MBBS PhDFRACP FRCPA, Sandra F. Deveridge, MDBSc,FRACP,FRCPA, Philip Arthur Rowlings, FRACP,FRCPA,MBBS,MS, Anthony K. Mills, MBBS, FRACP, FRCPA, Devinder S Gill, MBChB FRCPath MRCP, Peter G Bardy, MBBS, FRACP, FRCPA, Lynda Campbell, John F. Seymour, MD

Blood (2016) 128 (22): 338.

https://doi.org/10.1182/blood.V128.22.338.338

Published: 2016

Journal Articles

Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Constantine S. Tam, MBBS, Stephen Opat, MD, Gavin Cull, MBBS DM FRACP FRCPA, Judith Trotman, MBChB, David Gottlieb, MBBS MD FRACP FRCPA, David Simpson, MBChB, FRACP, FRCPA, Paula Marlton, MBBS, Mary Ann Anderson, MBBS, Matthew Ku, MBBS, David Ritchie, MD PhD, Sumita Ratnasingam, MBBS, Bradley Augustson, Mark Kirschbaum, MD, Lai Wang, PhD, Ling Xue, Jianxin Yang, Eric Hedrick, John F Seymour, Andrew W. Roberts

Blood (2016) 128 (22): 642.

https://doi.org/10.1182/blood.V128.22.642.642

Published: 2016

Journal Articles

High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy?

Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Joel Wight, MBBS, Kathryn Jackson, MBBS, Ashanka Mahilal Beligaswatte, BA, MBBS, MD FRACP, FRCPA, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Glen Kennedy, MBBS, FRACP, FRCPA, Louisa Martin, MBBS, Ian D. Lewis, MBBS PhD FRACP FRCPA, Devendra Hiwase, MBBS, FRACP, FRCPA, MD PhD, Daniela Zantomio, FRACP, FRCPA, MBBS, Simon Z. He, MBBS,FRACP,FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Kirk Morris, FRACP FRCPA MBBS, Peter Mollee, MBBS, MMedSc, FRACP, FRCPA, Paula Marlton, MBBS

Blood (2016) 128 (22): 3989.

https://doi.org/10.1182/blood.V128.22.3989.3989

Published: 2016

Journal Articles

Rare Variants Affecting the Fanconi Anaemia DNA Repair Genes Associate with Increased Risk for AML

Kyaw Ze Ya Maung, BSc, Paul Leo, PhD, Anna L Brown, PhD, Mahmoud A Bassal, Bsc, BCompSc, Debora A. Casolari, PhD, Adam Ewing, B.A & PhD, Emma Duncan, PhD, Sarah C Bray, PhD, Evgeny Glazov, PhD, Luen Bik To, MBBS, FRACP, FRCPA, PhD, Russell Saal, MMSc, BSMedTech, Ian D Lewis, MBBS, PhD FRACP, FRCPA, Devinder S Gill, MBChB FRCPath MRCP, Paula Marlton, MBBS, FRACP, FRCPA, James X Gray, MD PhD, Thomas J Gonda, PhD, Richard D'Andrea, PhD

Blood (2016) 128 (22): 41.

https://doi.org/10.1182/blood.V128.22.41.41

Published: 2016

Journal Articles

Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study

Andrew D Zelenetz, MD, PhD, Tadeusz Robak, MD, PhD, Bertrand Coiffier, MD, PhD, Julio Delgado, MD, Paula Marlton, MBBS, Adeboye H Adewoye, MD, Yeonhee Kim, PhD, Lyndah K. Dreiling, MD, Peter Hillmen, MB, ChB, PhD

Blood (2015) 126 (23): LBA-5.

https://doi.org/10.1182/blood.V126.23.LBA-5.LBA-5

Published: 2015

Journal Articles

Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome

Blood (2015) 126 (23): 1644.

https://doi.org/10.1182/blood.V126.23.1644.1644

Published: 2015

Journal Articles

Clinical Relevance of Partial Response in the Marrow (PRm) after Failure of Frontline Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML)

Shaun Fleming, MBBS (Hons), FRACP, FRCPA, Doen Ming Ong, MBBS, Kathryn Jackson, MBBS, FRACP, FRCPA, Sharon Avery, MBBS (Hons), FRACP, FRCPA, Peter Mollee, MBBS, MMedSc, FRACP, FRCPA, Paula Marlton, MBBS, FRACP, FRCPA, Glen A Kennedy, MBBS, FRACP, FRCPA, Andrew Wei, MBBS, FRACP, FRCPA, PhD

Blood (2015) 126 (23): 2512.

https://doi.org/10.1182/blood.V126.23.2512.2512

Published: 2015

Journal Articles

Prognostic Markers in Core-Binding Factor Acute Myeloid Leukaemia

Ashvind A Prabahran, MBBS, Mark Tacey, BSc, Shaun Fleming, MBBS (Hons), FRACP, FRCPA, Danielle Strong, Andrew Wei, MBBS, PhD, Courtney Tate, MBBS, Paula Marlton, MBBS, Joel Wight, MBBS, Andrew Grigg, MBBS, MD FRACP, FRACPA, Annabel Tuckfield, MBBS, FRACP, FRCPA, PhD, Jeff Szer, MB, BS, FRACP, David S. Ritchie, MDPhD, Lynette C.Y. Chee, MBBS, FRACP, FRCPA, PhD

Blood (2015) 126 (23): 2599.

https://doi.org/10.1182/blood.V126.23.2599.2599

Published: 2015

Journal Articles

Whole Exome Sequencing of Acute Myeloid Leukaemia Patients Identifies Somatic and Germline Mutations in Fanconi Anaemia Genes

Kyaw Zeya Maung, BSc, James X Gray, MD PhD, Paul J Leo, PhD, Mahmoud Bassal, BSc, Anna L Brown, PhD, Sarah C Bray, PhD, Ing Soo Tiong, MBChB, Chung H Kok, PhD, Andrew Deans, PhD, Mhairi Marshall, PhD, Brooke Gardiner, PhD, Evgeny A Glazov, PhD, Paula Marlton, MBBS, Devinder Gill, MD, Luen Bik To, MBBS, PhD, Ian D Lewis, MBBS, PhD, Richard J D'Andrea, PhD, Thomas J Gonda, PhD

Blood (2014) 124 (21): 698.

https://doi.org/10.1182/blood.V124.21.698.698

Published: 2014

Journal Articles

High Dose Cytarabine (HiDAC) and Fludarabine Without Anthracycline For Patients With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): The Australasian Leukaemia and Lymphoma Group (ALLG) AMLM13 Study

Paula Marlton, MBBS, John F Seymour, MBBS, PhD, Kenneth Bradstock, MBBS, PhD, Ian D Lewis, MB, BS, PhD, Russell Saal, BAppSci, MMedSci, Lyle McMillen, BSc, PhD, Juliana Di Iulio, BAppSc, PhD, Diana Zannino, BSc, MSc, Andrew Grigg, MBBS

Blood (2013) 122 (21): 1444.

https://doi.org/10.1182/blood.V122.21.1444.1444

Published: 2013

NARROW

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study

The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3 -ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3 -ITD Acute Myeloid Leukemia (ALLG AMLM16)

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study

Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non Hodgkin's Lymphoma

Metabolic Profiling of Adult Acute Myeloid Leukemia (AML)

High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study

Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival

Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy?

Rare Variants Affecting the Fanconi Anaemia DNA Repair Genes Associate with Increased Risk for AML

Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study

Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome

Clinical Relevance of Partial Response in the Marrow (PRm) after Failure of Frontline Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML)

Prognostic Markers in Core-Binding Factor Acute Myeloid Leukaemia

Whole Exome Sequencing of Acute Myeloid Leukaemia Patients Identifies Somatic and Germline Mutations in Fanconi Anaemia Genes

High Dose Cytarabine (HiDAC) and Fludarabine Without Anthracycline For Patients With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): The Australasian Leukaemia and Lymphoma Group (ALLG) AMLM13 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only